It's starting to filter into actual treatments. I've been doing research in the field of host-microbiome interactions for the last 8-10 years. And in the last c

It's starting to filter into actual treatments. I've been doing research in the field of host-microbiome interactions for the last 8-10 years. And in the last couple of years, it's gone from a fringe to a mainstream topic. I know a few places in Europe where they are already doing fecal microbiome transplants on a daily basis. For example, Quadram Institute & NHS Norwich. They have had some adverse events, so it's not totally safe, but I think the benefits already outweigh the risks if it's having a significant impact on your quality of life. New research avenues include, for example, doing a phage-only transplant. And obvious things like matching donors by HLA haplotypes. Both should improve safety. Still, I understand progress is too slow for patients. Most research institutions are pretty bad at polishing, industrializing and translating basic theories into clinical benefits. They just like to churn out small papers. I have sometimes considered to spin off as a non-profit maybe to speed things up. Theories are beginning to be understood quite well. It's mostly about cross-reactive bacterial epitopes and self antigens [1]. Plus metabolites. A very complex network, but some epitopes are central. For example, Ro60 in Lupus or insulin in T1D and their corresponding bacterial mimics. With sufficient data, we could easily throw in a personalized cocktail of phages that could halt many autoimmune disorders and tumors with high probability. That's the vision for the next 10 years, I think. [1] https://www.nature.com/articles/s41579-020-0367-2 https://www.nature.com/articles/s41579-020-0367-2